CHICAGO – Melanoma was the first cancer type in which immunotherapy went from promise to breakthrough, and the American Society of Clinical Oncology (ASCO) went back to those roots in its Monday press briefing, highlighting studies that explored the use of immunotherapy's founding father, Yervoy (ipilimumab, Bristol-Myers Squibb) in new ways, as well as other promising immunotherapies.